NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

PDS Biotechnology Corporation (PDSB) Stock Analysis

PDS Biotechnology Corporation (PDSB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PDSB

$0.22

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PDSB with… →

PDSB Key Statistics

As of Sep 4, 2026
Trading
Open
$0.22
Previous Close
$0.22
Day's Range
0.22–0.24
52-Week Range
0.20–1.55
Volume
1.08M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.45
Valuation
Market Cap
$12.31M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.97M
1-Year Return
−81.97%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PDSB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.43%
2025−52.76%
2024−67.20%
2023−62.35%
2022+62.96%
2021+278.50%
2020−19.25%
2019−58.72%
2018−96.57%
2017−25.04%
2016 (partial year)+33.12%

As of September 4, 2026.

PDSB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.50M—
2024$0.00−$37.61M—
2023$0.00−$42.94M—
2022$0.00−$40.85M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$31.54M−$34.50M—
2024$0.00—−$36.32M−$37.61M—
2023$0.00—−$43.05M−$42.94M—
2022$0.00—−$41.67M−$40.85M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PDSB Valuation vs Biotechnology Median

Median of 656 stocks
MetricPDSBBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

PDS Biotechnology Corporation (PDSB) carries a market capitalisation of $12.31M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 21 employees.

The 52-week range on file runs from $0.20 to $1.55. PDSB last closed at $0.22 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 12.82% above that 52-week low.

Financial Health

In fiscal 2025, PDS Biotechnology Corporation reported revenue of $0.00. The same year closed with a net loss of $34.50M. The reported profit margin is 0%. Trailing earnings per share are −0.64.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.45. Daily returns over the trailing 10 years annualize to a volatility of 103.57%. Over the trailing twelve months the price has returned −81.97%. Measured over 10 years, that is −48.84% a year compounded.

Growth & Income

The record shows no dividend for PDSB.

The strongest complete calendar year on file is 2021 at +278.50%; the weakest is 2018 at −96.57%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −71.43% year to date.

Peer Comparison

PDS Biotechnology Corporation (PDSB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PDS Biotechnology Corporation PDSB $12.31M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. PDS Biotechnology Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Visit website →